Ibrutinib and Venetoclax for First-Line Treatment of CLL
Volume: 380, Issue: 22, Pages: 2095 - 2103
Published: May 30, 2019
Abstract
Ibrutinib, an inhibitor of Bruton’s tyrosine kinase, and venetoclax, an inhibitor of B-cell lymphoma 2 protein, have been approved for patients with chronic lymphocytic leukemia (CLL). Preclinical investigations have indicated potential synergistic interaction of their...
Paper Details
Title
Ibrutinib and Venetoclax for First-Line Treatment of CLL
Published Date
May 30, 2019
Volume
380
Issue
22
Pages
2095 - 2103
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History